Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis

Mizunuma, Hideki; Taketani, Yuji; Ohta, Hiroaki; Honjo, Hideo; Gorai, Itsuo; Itabashi, Akira; Shiraki, Masataka

doi:10.3109/13697130902926910

Cited by 10 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…in BMD increases between 0.3 and 0.625 mg of oral CEE. Delmas et al found that 17-beta estradiol 1 mg/day increased BMD at the lumbar spine by 5.2%, and Mizunuma et al found comparable increases in lumbar spine BMD using either estradiol 1.0 mg/day or estradiol 0.5 mg/day [40,41].…”

Section: Low Dose and Transdermal Estrogens And Their Effect On Skele...mentioning

confidence: 99%

The role of menopausal hormone therapy in the prevention and treatment of low bone density in perimenopausal and postmenopausal women

Shah¹,

Ariel²

2023

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Purpose of reviewThe purpose of this review is to summarize the evidence on the benefits of menopausal hormone therapy (MHT) for the maintenance of skeletal health, prevention of osteoporosis and related fractures in peri and postmenopausal women.Recent findingsWe will review the impact of estrogen on skeletal health as well as the physiology of bone loss during the perimenopause and postmenopause. We will then elucidate the data that include estrogen alone and combination of MHT to demonstrate that in the absence of contraindication, MHT should be considered as an option for the maintenance of skeletal health both when concomitant menopausal symptoms are present and when not.SummaryIt has been well established that estrogens maintain bone mineral density (BMD) and reduce fracture risk at all sites. However, the most extensively studied form of estrogen with established fracture prevention is oral doses of synthetic estrogens. Due to the reduced risk profile, lower doses of bioidentical oral or transdermal estrogens are often preferred in clinical practice. We will highlight the current data on improvement in BMD and fracture risk reduction, including differences in formulation, dose, and route of delivery, to support a provider in the clinical decision-making process.

show abstract

Section: Low Dose and Transdermal Estrogens And Their Effect On Skele...mentioning

confidence: 99%

The role of menopausal hormone therapy in the prevention and treatment of low bone density in perimenopausal and postmenopausal women

Shah¹,

Ariel²

2023

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

Long term hormone therapy for perimenopausal and postmenopausal women

Marjoribanks¹,

Farquhar²,

Roberts³

et al. 2012

Cochrane Database of Systematic Reviews

158

115

View full text Add to dashboard Cite

HT is not indicated for primary or secondary prevention of cardiovascular disease or dementia, nor for preventing deterioration of cognitive function in postmenopausal women. Although HT is considered effective for the prevention of postmenopausal osteoporosis, it is generally recommended as an option only for women at significant risk, for whom non-oestrogen therapies are unsuitable. There are insufficient data to assess the risk of long term HT use in perimenopausal women or postmenopausal women younger than 50 years of age.

show abstract

Long-term hormone therapy for perimenopausal and postmenopausal women

Marjoribanks

Farquhar

Roberts

et al. 2017

Cochrane Database of Systematic Reviews

290

306

View full text Add to dashboard Cite

BACKGROUND: Hormone therapy (HT) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women. This is an updated version of a Cochrane review first published in 2005. OBJECTIVES: To assess effects of long-term HT (at least 1 year's duration) on mortality, cardiovascular outcomes, cancer, gallbladder disease, fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment. SEARCH METHODS: We searched the following databases to September 2016: Cochrane Gynaecology and Fertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and PsycINFO. We searched the registers of ongoing trials and reference lists provided in previous studies and systematic reviews. SELECTION CRITERIA: We included randomised double-blinded studies of HT versus placebo, taken for at least 1 year by perimenopausal or postmenopausal women. HT included oestrogens, with or without progestogens, via the oral, transdermal, subcutaneous or intranasal route. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies, assessed risk of bias and extracted data. We calculated risk ratios (RRs) for dichotomous data and mean differences (MDs) for continuous data, along with 95% confidence intervals (CIs). We assessed the quality of the evidence by using GRADE methods. MAIN RESULTS: We included 22 studies involving 43,637 women. We derived nearly 70% of the data from two well-conducted studies (HERS 1998; WHI 1998). Most participants were postmenopausal American women with at least some degree of comorbidity, and mean participant age in most studies was over 60 years. None of the studies focused on perimenopausal women.In relatively healthy postmenopausal women (i.e. generally fit, without overt disease), combined continuous HT increased the risk of a coronary event (after 1 year's use: from 2 per 1000 to between 3 and 7 per 1000), venous thromboembolism (after 1 year's use: from 2 per 1000 to between 4 and 11 per 1000), stroke (after 3 years' use: from 6 per 1000 to between 6 and 12 per 1000), breast cancer (after 5.6 years' use: from 19 per 1000 to between 20 and 30 per 1000), gallbladder disease (after 5.6 years' use: from 27 per 1000 to between 38 and 60 per 1000) and death from lung cancer (after 5.6 years' use plus 2.4 years' additional follow-up: from 5 per 1000 to between 6 and 13 per 1000).Oestrogen-only HT increased the risk of venous thromboembolism (after 1 to 2 years' use: from 2 per 1000 to 2 to 10 per 1000; after 7 years' use: from 16 per 1000 to 16 to 28 per 1000), stroke (after 7 years' use: from 24 per 1000 to between 25 and 40 per 1000) and gallbladder disease (after 7 years' use: from 27 per 1000 to between 38 and 60 per 1000) but reduced the risk of breast cancer (after 7 years' use: from 25 per 1000 to between 15 and 25 per 1000) and clinical fracture (after 7 years' use: from 141 per 1000 to between 92 and 113 per 1...

show abstract

Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis

Abstract: This study showed that E(2), at both 1.0 mg and 0.5 mg doses, was effective in increasing bone mineral density with an acceptable safety and tolerability profile in Japanese postmenopausal women with osteoporosis but that the bone mineral density response was higher with the 1.0 mg dose.

Cited by 10 publications

References 28 publications

The role of menopausal hormone therapy in the prevention and treatment of low bone density in perimenopausal and postmenopausal women

The role of menopausal hormone therapy in the prevention and treatment of low bone density in perimenopausal and postmenopausal women

Long term hormone therapy for perimenopausal and postmenopausal women

Long-term hormone therapy for perimenopausal and postmenopausal women

Contact Info

Product

Resources

About